Foghorn Therapeutics Profit Margin

The latest profit margin for FHTX is -2.67% as of March 2026. That compares with -3.42% in the prior-year period — up 22.0% year over year. That is below the Healthcare sector average of 15.52%. Investors often review this figure alongside Foghorn Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, FHTX's profit margin moved from -3.42% to -2.67% — a 22.0% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Foghorn Therapeutics's valuation or profitability profile.

Against Healthcare companies, FHTX currently prints -2.67% for profit margin, while the sector average sits near 15.52%. That is roughly 1819.6% below the sector mean. Large gaps often invite a closer look at Foghorn Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Foghorn Therapeutics converts resources into returns. At -2.67%, FHTX may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -3.42% in the prior-year period — up 22.0% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting FHTX's profit margin (-2.67%), review year-over-year change from -3.42%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.